Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening - Wikidata - awgldk - TriplyDB

Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening

Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening

http://www.wikidata.org/entity/Q34701235

about

Calcium-activated chloride channel ANO1 promotes breast cancer progression by activating EGFR and CAMK signaling Endocrine fibroblast growth factors 15/19 and 21: from feast to famine Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection Recent advances in understanding and managing cholestasis Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?Targeting cancer with kinase inhibitors Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors The Ca(2+) -activated Cl(-) channel, ANO1 (TMEM16A), is a double-edged sword in cell proliferation and tumorigenesis Fibroblast growth factors in cardiovascular disease: The emerging role of FGF21 Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges Regulation of amphiregulin gene expression by β-catenin signaling in human hepatocellular carcinoma cells: a novel crosstalk between FGF19 and the EGFR system Therapeutic utilities of fibroblast growth factor 19.ReactomeFIViz: a Cytoscape app for pathway and network-based data analysis.sCNAphase: using haplotype resolved read depth to genotype somatic copy number alterations from low cellularity aneuploid tumors.Recurrent hemizygous deletions in cancers may optimize proliferative potential Whole genome sequencing of matched tumor, adjacent non-tumor tissues and corresponding normal blood samples of hepatocellular carcinoma patients revealed dynamic changes of the mutations profiles during hepatocarcinogenesis.Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis.Is fibroblast growth factor receptor 4 a suitable target of cancer therapy?New knowledge of the mechanisms of sorafenib resistance in liver cancer Focal gains of VEGFA: candidate predictors of sorafenib response in hepatocellular carcinoma.Identification of drivers from cancer genome diversity in hepatocellular carcinoma.Genome-wide screening for genetic alterations in esophageal cancer by aCGH identifies 11q13 amplification oncogenes associated with nodal metastasis Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma.Systems consequences of amplicon formation in human breast cancer Detection of tumor cell-specific mRNA and protein in exosome-like microvesicles from blood and saliva Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells.Two Distinct Categories of Focal Deletions in Cancer Genomes.Comparative oncogenomic analysis of copy number alterations in human and zebrafish tumors enables cancer driver discovery Reciprocal interaction of Wnt and RXR-α pathways in hepatocyte development and hepatocellular carcinoma.The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer.Bile Acids as Hormones: The FXR-FGF15/19 Pathway Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib.A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions Activation of multiple cancer pathways and tumor maintenance function of the 3q amplified oncogene FNDC3B Gene Network Analysis of Glucose Linked Signaling Pathways and Their Role in Human Hepatocellular Carcinoma Cell Growth and Survival in HuH7 and HepG2 Cell Lines.Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.Life in the fast lane: mammalian disease models in the genomics era.Loss of fragile histidine triad and amplification of 1p36.22 and 11p15.5 in primary gastric adenocarcinomas.Quantitative liver proteomics identifies FGF19 targets that couple metabolism and proliferation.

P2860

Q24602862-A9AA85F6-6488-49FA-8A4C-7461505AC468 Q24629260-636E53C0-551E-4649-B221-95617D595692 Q26738860-F0827D65-D654-4ED2-AD30-9BAC5624F7F1 Q26748537-C8D368A0-BC0F-4A42-A0B6-9E745CC469B0 Q26766689-2A2F2DBE-72C9-4A72-8A75-A2AD7FEDE1E5 Q26865765-93A125AB-7932-4985-ADDD-DE5062042D72 Q26998790-56176A3D-10AA-4FA0-93CC-CA825C008345 Q27011764-1D7338F6-1741-4F39-AD2F-10878375CAC6 Q28084197-811D566D-CB0F-46BB-A6A9-553D80C45923 Q28272678-4AD42B10-FA08-43B0-8948-6B4722707E24 Q28484499-B4AB3252-D459-4414-BA25-67141C4FDFAB Q30407643-A778667D-8951-4804-AE55-507F37113ECC Q30859718-CAF2718B-01BA-46B3-A71E-058D5AA187D0 Q33558237-3AC50570-5666-43DE-B855-47C9DC0F53D9 Q33637152-FC10AF46-66AC-4B2B-BF82-EAB6E07498C4 Q33688583-3CA6409A-6B82-488B-81C2-F63642557A3C Q33716459-EDBB2067-ABD6-46ED-8207-B4CAB43D01AE Q33751398-48FC3027-2246-4575-89C2-B20422B44EFA Q33759933-85E71FC4-BA0D-49A7-9838-6B76BDE2C92D Q33807832-89703808-A42E-45E7-B064-69DDDF3D31C3 Q33907993-1E6E43F8-4E7C-4C74-B41A-C673B02FBC66 Q34326537-4EF95407-CAF0-42C1-9559-E49581A18CFD Q34330744-7EAE1244-0E87-44C5-95CD-4B167782B162 Q34350077-B05930A2-6C46-434D-A97D-655E0664BC9B Q34513049-6BF77991-593D-4391-9232-0384F278C324 Q34775779-EAAA1C09-E321-4E7C-9C4E-D811BC3300D0 Q34785286-C149E418-B84C-44E1-8B26-B73FC09FF6B5 Q34979403-73C0802D-5F30-4E75-A660-F3A781CBED92 Q35147588-405102A7-DE8C-457A-B4D7-C3E47270393C Q35204533-D6539314-FA71-421E-9277-1D65AECC1AE5 Q35250612-333B58EA-FC33-434D-82A9-5773E961782F Q35737058-CA11E098-DF85-494B-807F-095DA2782B51 Q35911679-C8094EA3-B610-4A1D-BFD6-F59E8AA2A0D0 Q35991696-9F9219B4-BDED-468C-A4AC-C03DA6A9A297 Q36023727-4D8C806B-47B6-4F3B-AA01-278C75AC9370 Q36031886-5D19F267-60EB-43A2-AE72-4282C44EA2A9 Q36104399-C8873BF4-8DE1-460B-A73E-50E485B49474 Q36135110-24784AEE-68A3-4F18-9576-5522565997D9 Q36214558-A14AF807-58E0-4C13-9AF3-640BFCDCA3A3 Q36274229-FDE8B56A-58DF-402D-A350-1BE4745F0D41

P2860

Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening

http://www.wikidata.org/entity/Q34701235

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Identification of a therapeuti ...... ancer by Oncogenomic screening

@ast

Identification of a therapeuti ...... ancer by Oncogenomic screening

@en

Identification of a therapeuti ...... ancer by Oncogenomic screening

@nl

type

label

Identification of a therapeuti ...... ancer by Oncogenomic screening

@ast

Identification of a therapeuti ...... ancer by Oncogenomic screening

@en

Identification of a therapeuti ...... ancer by Oncogenomic screening

@nl

prefLabel

Identification of a therapeuti ...... ancer by Oncogenomic screening

@ast

Identification of a therapeuti ...... ancer by Oncogenomic screening

@en

Identification of a therapeuti ...... ancer by Oncogenomic screening

@nl

P1433

Q34701235-1CD53571-E8CC-41A1-8BB7-518156BE8FFC

P1476

Q34701235-448ED98B-3DF8-45B2-B7CB-0BE33EE9F7BF

P2093

Q34701235-009F6A52-40FB-44F3-8A8D-7DE0610CCB62

Q34701235-09BEBA6E-5031-4AC4-8E86-C80E37DCF5D4

Q34701235-0E10C85A-3D7B-45AA-8118-FD834010A4F9

Q34701235-33A6CC96-1444-4093-86F3-465EFDE2667F

Q34701235-41FAF499-932F-4473-A45C-30C519D36D66

Q34701235-42398472-88F7-43B6-A7AA-7D89B6155E43

Q34701235-5E401F26-F5AA-4820-B70E-65DD69F39869

Q34701235-7430107E-145A-442D-96CB-96D969178D5C

Q34701235-8C0C6794-9042-4F4C-AA1D-6DE7E7D048F4

Q34701235-B1C0A3BB-78C8-4186-87F6-459B3F443212

P2860

Q34701235-070BB2AE-F149-45B1-9336-323B40D35F5C

Q34701235-0DB69747-A602-4CC2-8B88-7CB95A085D76

Q34701235-22A8EDD3-CEF8-4796-AD53-635D758DE04D

Q34701235-22FFD42E-6F9A-4C98-A82D-E975B2150096

Q34701235-27D927E4-5B3B-4D16-84B4-2BDEC65361C6

Q34701235-2EA6D090-47CE-4582-B045-4E1FDAA0621D

Q34701235-2F842769-EF26-4735-8949-9F54B787CE32

Q34701235-34318095-7BFF-46E5-BF1C-44B1929529D1

Q34701235-37EB98B8-6CFC-42A9-9107-21C4046DDA24

Q34701235-3BF96961-12D6-4A31-B688-E63C184AA301

P304

Q34701235-F86B8496-1CFB-454E-985C-BD6795FB3BE4

P31

Q34701235-C0D89FFE-9AF5-411E-937D-69563D951EC5

P356

Q34701235-DE966045-C09C-4BAA-B843-FDBA5AF0781B

P433

Q34701235-EA22EC14-41B8-498D-AF3B-2D87A1E8B5DD

P478

Q34701235-BD8BA503-046C-4D62-909C-D15BF4BF4C74

P50

Q34701235-00934965-06D0-492A-AA82-FEDBA1FC89A2

Q34701235-61C8FFF8-6469-4142-9296-1A6B1CFD94D7

P577

Q34701235-D6D29AAB-C7F5-4DDC-AD9F-BD345428A575

P5875

Q34701235-F07565CF-C3EF-4067-B4B8-BFE9332793A3

P698

Q34701235-DB415CFD-CA6A-4712-80A4-109E72FE291A

P932

Q34701235-939E391F-F0F6-4652-940C-E54F4887140A

P356

J.CCR.2011.01.040

P1433

P1476

Identification of a therapeuti ...... ancer by Oncogenomic screening

@en

P2093

Alice Zhao

http://www.w3.org/2001/XMLSchema#string

Chunlin Cai

http://www.w3.org/2001/XMLSchema#string

Dorothy M French

http://www.w3.org/2001/XMLSchema#string

Eric T Sawey

http://www.w3.org/2001/XMLSchema#string

Guanming Wu

http://www.w3.org/2001/XMLSchema#string

Herman Yee

http://www.w3.org/2001/XMLSchema#string

Jianping Zhang

http://www.w3.org/2001/XMLSchema#string

Lars Zender

http://www.w3.org/2001/XMLSchema#string

Maia Chanrion

http://www.w3.org/2001/XMLSchema#string

Richard S Finn

http://www.w3.org/2001/XMLSchema#string

P2860

Immunoaffinity profiling of tyrosine phosphorylation in cancer cells

The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)

Serine/threonine kinase Pim-2 promotes liver tumorigenesis induction through mediating survival and preventing apoptosis of liver cell

High-resolution genomic profiles of human lung cancer

Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach

Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer

A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice

Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells

Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation

Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling

P304

347-358

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CCR.2011.01.040

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50376043

http://www.w3.org/2001/XMLSchema#string

P698

21397858

http://www.w3.org/2001/XMLSchema#string

P932

3061399

http://www.w3.org/2001/XMLSchema#string